MxT Biotech Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
11
MxT Biotech General Information
Description
Developer of microfluid-based intracellular material delivery designed to offer gene-editing services and automated process equipment. The company offers cell therapy products like mecha operators, which are non-viral-based intracellular mass transfer platforms, enabling professionals to deliver genes and nucleic acids into cells by creating gaps in the cell and nuclear membranes using the flow generated in microtubules.
Contact Information
Website
www.mxtbiotech.comCorporate Office
- 48, Ttukseom-ro 17ga-gil
- Seongdong-gu
- Seoul, 04785
- South Korea
Corporate Office
- 48, Ttukseom-ro 17ga-gil
- Seongdong-gu
- Seoul, 04785
- South Korea
MxT Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 04-Jul-2023 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 15-May-2022 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2022 | Completed | Generating Revenue | |||
| 3. Seed Round | 15-Jul-2021 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. University Spin-Out | 03-Mar-2021 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MxT Biotech Patents
MxT Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025088687-A | Intracellular substance transport platform of droplet base | Active | 30-Nov-2023 | ||
| US-20250177984-A1 | Platform for intracellular delivery using droplet microfluidics | Pending | 30-Nov-2023 | ||
| EP-4324926-A1 | Intracellular delivery platform | Inactive | 12-Apr-2021 | ||
| EP-4324926-A4 | Intracellular delivery platform | Inactive | 12-Apr-2021 | ||
| US-20240158729-A1 | Intracellular delivery platform | Pending | 12-Apr-2021 | C12M35/04 |
MxT Biotech Signals
MxT Biotech Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IBK Changgong | Accelerator/Incubator | |||
| Tech Incubator Program for Startup | Accelerator/Incubator | |||
| BNK Venture Capital | Venture Capital | Minority | ||
| DAYLI Partners | Venture Capital | Minority | ||
| Hyundai Investment Partners | Asset Manager | Minority |
MxT Biotech FAQs
-
When was MxT Biotech founded?
MxT Biotech was founded in 2021.
-
Where is MxT Biotech headquartered?
MxT Biotech is headquartered in Seoul, South Korea.
-
What is the size of MxT Biotech?
MxT Biotech has 16 total employees.
-
What industry is MxT Biotech in?
MxT Biotech’s primary industry is Discovery Tools (Healthcare).
-
Is MxT Biotech a private or public company?
MxT Biotech is a Private company.
-
What is MxT Biotech’s current revenue?
The current revenue for MxT Biotech is .
-
How much funding has MxT Biotech raised over time?
MxT Biotech has raised $4.01M.
-
Who are MxT Biotech’s investors?
IBK Changgong, Tech Incubator Program for Startup, BNK Venture Capital, DAYLI Partners, and Hyundai Investment Partners are 5 of 11 investors who have invested in MxT Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process